https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46788 Wed 30 Nov 2022 13:21:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45277 0.14). Conclusion: In this secondary analysis of a primary efficacy study, PD was a common comorbidity among those with MDD, but was not a significant predictor of functional outcomes. This study adds to the limited literature on PD in randomized controlled trials for MDD.]]> Wed 26 Oct 2022 17:13:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39815 I² statistic. This systematic review was registered with PROSPERO (CRD42018089279) and the protocol is published. Results: The search yielded 11,640 studies. Subsequent to removing duplicates, 9657 studies were screened at title and abstract stage and 1456 were assessed at full-text stage. Eighteen studies met criteria for inclusion in this review. Meta-analysis did not reveal a significant difference between groups for treatment outcome (standardised mean difference 0.22 [-0.09, 0.54]; I²: 69%, p=0.17) and remission (risk ratio 0.84 [0.64, 1.11]; I²: 51%, p=0.22). Limitations: This review was limited by lack of studies on bipolar disorder. Conclusion: PD comorbidity does not appear to affect treatment efficacy of pharmacological interventions for adults with mood disorders.]]> Wed 10 Aug 2022 13:16:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51427 Tue 05 Sep 2023 17:47:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54278 Thu 15 Feb 2024 14:38:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49523 Sat 20 May 2023 12:39:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39177 n = 133). Participants received 16 weeks adjunctive treatment of either placebo or N-acetylcysteine-alone or a combination of mitochondrial-enhancing nutraceuticals including N-acetylcysteine (combination treatment). Participants were followed up 4 weeks post-treatment discontinuation (Week 20). Diet was assessed by the Cancer Council Victoria Dietary Questionnaire for Epidemiological Studies, Version 2, converted into an Australian Recommended Food Score to measure diet quality, and energy-adjusted dietary inflammatory index score to measure inflammatory potential of diet. Body mass index was also measured. Generalised estimating equation models were used to assess whether diet quality, energy-adjusted dietary inflammatory index score and/or body mass index were predictors of response to significant outcomes of the primary trial: depression symptoms, clinician-rated improvement and functioning measures. Results: In participants taking combination treatment compared to placebo, change in depression scores was not predicted by Australian Recommended Food Score, dietary inflammatory index or body mass index scores. However, participants with better diet quality (Australian Recommended Food Score) reported reduced general depression and bipolar depression symptoms (p = 0.01 and p = 0.03, respectively) and greater clinician-rated improvement (p = 0.02) irrespective of treatment and time. Participants who had a more anti-inflammatory dietary inflammatory index had less impairment in functioning (p = 0.01). Combination treatment may attenuate the adverse effects of pro-inflammatory diet (p = 0.03) on functioning. Participants with lower body mass index who received combination treatment (p = 0.02) or N-acetylcysteine (p = 0.02) showed greater clinician-rated improvement. Conclusion: These data support a possible association between diet (quality and inflammatory potential), body mass index and response to treatment for bipolar depression in the context of a nutraceutical trial. The results should be interpreted cautiously because of limitations, including numerous null findings, modest sample size and being secondary analyses.]]> Mon 23 May 2022 14:53:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52335 Mon 09 Oct 2023 14:50:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45466 n = 114 participants with completed cognitive outcomes at follow up were included in this analysis. Using the Cogstate Brief Battery, the following cognitive outcomes were assessed: psychomotor function, attention, visual learning and memory (visual and working). Subgroup analyses investigated whether baseline clinical parameters (baseline cognitive functioning, illness severity and duration, depressive symptoms) moderated the relationship between mangosteen pericarp extract intervention and change in cognitive outcomes. Results: There were no significant between-group changes in any cognitive outcomes assessed. Subgroup analysis based on baseline cognition and clinical characteristics did not reveal any significant between-group difference in change. Conclusions: Mangosteen pericarp extract did not affect cognitive outcomes in people with schizophrenia. Further investigation regarding optimal dosing strategies for mangosteen interventions and the testing of additional cognitive domains may be warranted.]]> Fri 28 Oct 2022 14:45:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51700 Fri 15 Sep 2023 10:39:15 AEST ]]>